Rokit Healthcare Expands Trial of AI-Powered Cartilage Regeneration Treatment
Rokit Healthcare is accelerating commercialization of a cartilage regeneration platform that uses artificial intelligence and 3D bioprinting. The company is running a clinical trial across 13 medical institutions with over 100 patients-described as the first large-scale multi-center study combining AI and bioprinting for cartilage repair.
The trial, called TCW (Timeless Cartilage, Comfortable Work), is overseen by Jang Jong-beom, a professor of orthopedic surgery at Seoul National University Bundang Hospital. The work addresses a persistent problem: damaged cartilage rarely heals naturally, and existing treatments often produce inferior tissue.
Why Current Treatments Fall Short
Microfracture is the most common cartilage repair procedure. Surgeons create tiny perforations in the damaged area to trigger bone marrow cells to regenerate tissue. The surgery is relatively simple, but the result is fibrocartilage-a weaker tissue that resembles normal cartilage only superficially.
Autologous stem cell treatments offer another option but require extracting cells, culturing them externally for weeks, and performing two separate surgeries. This extended timeline and dual-surgery approach limits practical use.
How the New Platform Works
Rokit's technology uses the infrapatellar fat pad (IFP), an autologous adipose tissue from the patient's own knee. The fat is micronized into bio-ink and implanted via 3D printing directly into the damaged cartilage area.
The process happens in one procedure. AI analyzes the patient's defect, and a 3D bioprinter outputs a customized cartilage patch in real time using the patient's own fat-based material. No external culturing. No second surgery.
Because the treatment uses autologous tissue, immune rejection risk drops significantly compared to donor or animal-derived materials. The regenerated tissue aims to be hyaline cartilage-the same durable tissue found in healthy joints.
What's Next
Jang said the platform will evolve to incorporate stem cells and growth factors alongside autologous adipose tissue. Eventually, surgeons may print cartilage directly onto the patient's knee during the procedure itself.
The trial results will determine whether this approach delivers the durability and function that microfracture and stem cell treatments have struggled to achieve. For healthcare professionals managing cartilage damage, the outcome could shift treatment options significantly.
Learn more about AI for Healthcare and AI for Science & Research.
Your membership also unlocks:
